Santen Pharmaceutical Software Purchases and Digital Transformation Initiatives

Discover the latest software purchases and digital transformation initiatives being undertaken by Santen Pharmaceutical and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 4315 Santen Pharmaceutical employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.

During our research, we have identified that Santen Pharmaceutical has purchased the following applications: Medidata Edge CTMS for Clinical Trial Management in 2018, Kinaxis RapidResponse for Supply Chain Management in 2017, SAP S/4 HANA for ERP Financial in 2019 and the related IT decision-makers and key stakeholders.

Our database provides customer insight and contextual information on which enterprise applications and software systems Santen Pharmaceutical is running and its propensity to invest more and deepen its relationship with Medidata Solutions , Kinaxis , SAP or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.

We have been analyzing Santen Pharmaceutical revenues, which have grown to $2.31 billion in 2023, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for Santen Pharmaceutical intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.

About the Customer

Santen innovating therapies to improve the quality of life for patients worldwide.The Company single focus in ophthalmology enables to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment.

With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future.

Scope and Challenges

On June 19, 2017, Santen Pharmaceutical announced that has selected Kinaxis RapidResponse to plan concurrently across functions and time periods for end-to-end visibility across the entire supply chain.

Ultimately, the company wanted a single end-to-end planning platform that would reduce global planning cycle times and raise efficiency. Following a thorough evaluation, Santen selected Kinaxis RapidResponse because of its concurrent planning capabilities.

With the deployment of RapidResponse, Santen will reduce global planning times, manual activity and eliminate the use of multiple disconnected spreadsheets. Having a consolidated view of the entire supply chain, Santen will plan for its expected performance, monitor its progress, and respond to variations to the plan as reality hits.

Santen Pharmaceutical chose Kinaxis to develop a consolidated view of the entire supply chain to collapse decision cycle times by connecting all links in supply chain. Through RapidResponse, Santen will remove supply chain planning functional boundaries and gain the critical capabilities to drive tangible business outcomes

Outcome and Implications 

On February 20, 2018 - Santen Pharmaceutical Co., Ltd, is expanding its use of the Medidata Clinical Cloud® with the adoption of Edge CTMS (Clinical Trial Management System) to support its clinical trial operations, in ophthalmology, across Japan, Asia, USA, and the EU. Santen becomes the first sponsor to adopt Medidata Edge CTMS in the Japanese market.

As Santen strives to globalize its research and development operations, the company will deploy Edge CTMS to streamline trial activities, increase productivity and improve efficiency of trial execution.

Edge CTMS provides real-time visibility into clinical trial milestones, allowing Santen to evaluate operational effectiveness and implement changes rapidly. It also seamlessly integrates with Rave EDC, the industry-leading EDC solution, enabling Santen to dramatically speed trial execution by managing both study and trial data on a single unified platform.

Quotes

Global organizations appreciate that to achieve breakthrough results they need to leverage the capabilities of an innovative approach. We are excited that RapidResponse has been selected by Santen, our first Japanese headquartered pharmaceutical customer, as its supply chain planning system of record. RapidResponse is a powerful concurrent planning platform, used by many leading life sciences organizations, that will enable them to know sooner and act faster, revolutionizing how they perform supply chain planning functions to drive improved corporate performance,” said John Sicard, Chief Executive Officer at Kinaxis. 

“There is a growing demand to simplify, improve efficiency and create transparency across clinical trials. The Medidata Edge CTMS solution makes it possible for life science companies to achieve all three on our unified platform. We look forward to strengthening our relationship with Santen, and helping to streamline workflows across their R&D, globally, ” said Glen de Vries, Medidata president, and co-founder.